NEW YORK, Feb. 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Umpqua Holdings Corporation (NASDAQ:UMPQ), Westrock Company (NYSE:WRK), Globus Medical, Inc. (NYSE:GMED), Procter & Gamble Company (NYSE:PG), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), and Cree, Inc. (NASDAQ:CREE), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
UMPQ DOWNLOAD: http://Fundamental-Markets.com/register/?so=UMPQ
WRK DOWNLOAD: http://Fundamental-Markets.com/register/?so=WRK
GMED DOWNLOAD: http://Fundamental-Markets.com/register/?so=GMED
PG DOWNLOAD: http://Fundamental-Markets.com/register/?so=PG
ACAD DOWNLOAD: http://Fundamental-Markets.com/register/?so=ACAD
CREE DOWNLOAD: http://Fundamental-Markets.com/register/?so=CREE
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine Umpqua Holdings Corporation (NASDAQ:UMPQ), Westrock Company (NYSE:WRK), Globus Medical, Inc. (NYSE:GMED), Procter & Gamble Company (NYSE:PG), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), and Cree, Inc. (NASDAQ:CREE) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed February 13th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
UMPQUA HOLDINGS CORPORATION (UMPQ) REPORT OVERVIEW
Umpqua's Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, Umpqua reported interest income of $240.72MM vs $226.42MM (up 6.31%) and basic earnings per share $0.28 vs $0.28 (unchanged). For the twelve months ended December 31st, 2016 vs December 31st, 2015, Umpqua reported interest income of $910.64MM vs $929.87MM (down 2.07%) and basic earnings per share $1.06 vs $1.01 (up 4.95%). Umpqua is expected to report earnings on April 18th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.21. The estimated EPS forecast for the next fiscal year is $1.59 and is expected to report on January 22nd, 2019.
To read the full Umpqua Holdings Corporation (UMPQ) report, download it here: http://Fundamental-Markets.com/register/?so=UMPQ
-----------------------------------------
WESTROCK COMPANY (WRK) REPORT OVERVIEW
Westrock's Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, Westrock reported revenue of $3,894.00MM vs $3,447.20MM (up 12.96%) and basic earnings per share $4.45 vs $0.32 (up 1,290.63%). For the twelve months ended September 30th, 2017 vs September 30th, 2016, Westrock reported revenue of $14,859.70MM vs $14,171.80MM (up 4.85%) and basic earnings per share $2.81 vs -$1.56. Westrock is expected to report earnings on April 25th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.54. The estimated EPS forecast for the next fiscal year is $4.54 and is expected to report on November 1st, 2018.
To read the full Westrock Company (WRK) report, download it here: http://Fundamental-Markets.com/register/?so=WRK
-----------------------------------------
GLOBUS MEDICAL, INC. (GMED) REPORT OVERVIEW
Globus Medical's Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, Globus Medical reported revenue of $151.74MM vs $135.65MM (up 11.86%) and basic earnings per share $0.27 vs $0.27 (unchanged). For the twelve months ended December 31st, 2016 vs December 31st, 2015, Globus Medical reported revenue of $563.99MM vs $544.75MM (up 3.53%) and basic earnings per share $1.09 vs $1.19 (down 8.40%). Globus Medical is expected to report earnings on February 21st, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.31. The estimated EPS forecast for the next fiscal year is $1.47 and is expected to report on February 21st, 2018.
To read the full Globus Medical, Inc. (GMED) report, download it here: http://Fundamental-Markets.com/register/?so=GMED
-----------------------------------------
PROCTER & GAMBLE COMPANY (PG) REPORT OVERVIEW
Procter & Gamble's Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, Procter & Gamble reported revenue of $17,395.00MM vs $16,856.00MM (up 3.20%) and basic earnings per share $0.96 vs $3.01 (down 68.11%). For the twelve months ended June 30th, 2017 vs June 30th, 2016, Procter & Gamble reported revenue of $65,058.00MM vs $65,299.00MM (down 0.37%) and basic earnings per share $5.80 vs $3.80 (up 52.63%). Procter & Gamble is expected to report earnings on April 25th, 2018. The report will be for the fiscal period ending March 31st, 2018. According to Zacks Investment Research, based on 8 analysts' forecasts, the consensus EPS forecast for the quarter is $1.15. The reported EPS for the same quarter last year was $0.96. The estimated EPS forecast for the next fiscal year is $4.53 and is expected to report on July 26th, 2018.
To read the full Procter & Gamble Company (PG) report, download it here: http://Fundamental-Markets.com/register/?so=PG
-----------------------------------------
ACADIA PHARMACEUTICALS INC. (ACAD) REPORT OVERVIEW
ACADIA Pharmaceuticals' Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, ACADIA Pharmaceuticals reported revenue of $35.58MM vs $5.27MM (up 575.36%) and basic earnings per share -$0.53 vs -$0.61. For the twelve months ended December 31st, 2016 vs December 31st, 2015, ACADIA Pharmaceuticals reported revenue of $17.33MM vs $0.06MM (up 28,311.48%) and basic earnings per share -$2.34 vs -$1.63. ACADIA Pharmaceuticals is expected to report earnings on February 27th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.65. The estimated EPS forecast for the next fiscal year is -$1.63 and is expected to report on February 27th, 2018.
To read the full ACADIA Pharmaceuticals Inc. (ACAD) report, download it here: http://Fundamental-Markets.com/register/?so=ACAD
-----------------------------------------
CREE, INC. (CREE) REPORT OVERVIEW
Cree's Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, Cree reported revenue of $367.87MM vs $401.33MM (down 8.34%) and basic earnings per share $0.14 vs $0.06 (up 133.33%). For the twelve months ended June 30th, 2017 vs June 30th, 2016, Cree reported revenue of $1,473.00MM vs $1,616.63MM (down 8.88%) and basic earnings per share -$1.00 vs -$0.21. Cree is expected to report earnings on April 24th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.11. The estimated EPS forecast for the next fiscal year is -$0.10 and is expected to report on August 28th, 2018.
To read the full Cree, Inc. (CREE) report, download it here: http://Fundamental-Markets.com/register/?so=CREE
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com
© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.